1. Home
  2. EIC vs SABS Comparison

EIC vs SABS Comparison

Compare EIC & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

EIC

Eagle Point Income Company Inc.

HOLD

Current Price

$9.41

Market Cap

223.3M

Sector

Finance

ML Signal

HOLD

Logo SAB Biotherapeutics Inc.

SABS

SAB Biotherapeutics Inc.

HOLD

Current Price

$3.76

Market Cap

201.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EIC
SABS
Founded
N/A
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
223.3M
201.4M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
EIC
SABS
Price
$9.41
$3.76
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
5
Target Price
$12.63
$9.80
AVG Volume (30 Days)
149.3K
822.8K
Earning Date
02-26-2026
05-08-2026
Dividend Yield
13.94%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$9.08
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.17
$1.09
52 Week High
$14.83
$6.60

Technical Indicators

Market Signals
Indicator
EIC
SABS
Relative Strength Index (RSI) 42.00 43.96
Support Level $9.25 $3.69
Resistance Level $10.15 $4.16
Average True Range (ATR) 0.17 0.16
MACD 0.04 -0.01
Stochastic Oscillator 52.27 20.97

Price Performance

Historical Comparison
EIC
SABS

About EIC Eagle Point Income Company Inc.

Eagle Point Income Co Inc is a closed-end management investment company. Its primary investment objective is to generate high current income, with a secondary objective to generate capital appreciation. The Company seeks to achieve its investment objectives by investing in junior debt tranches of collateralized loan obligations, or "CLOs," that are collateralized by a portfolio consisting of below-investment grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors.

About SABS SAB Biotherapeutics Inc.

SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.

Share on Social Networks: